OpenLB
Open Library of Bioscience
Advanced Search
Drug delivery
Nov, 2017;24 (1): 1909-1926.

Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy.

Shan-Shan Qi, Jia-Hui Sun, Hao-Han Yu, Shu-Qin Yu
Author Information
  1. Shan-Shan Qi: a Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology , College of Life Sciences, Nanjing Normal University , Nanjing , The People's Republic of China.
  2. Jia-Hui Sun: a Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology , College of Life Sciences, Nanjing Normal University , Nanjing , The People's Republic of China.
  3. Hao-Han Yu: c Nanjing DeBioChem Inc , Nanjing , The People's Republic of China.
  4. Shu-Qin Yu: a Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology , College of Life Sciences, Nanjing Normal University , Nanjing , The People's Republic of China. ORCID
PMID: 29191057 DOI: 10.1080/10717544.2017.1410256

Abstract

To achieve superior therapeutic efficacy, the combination chemotherapy using two or more anticancer drugs in clinical practice has been generally accepted as a feasible strategy. On account of the concept of combination chemotherapy, co-delivery of anticancer drugs with nanotechnology gradually becomes a desired strategy and one of the research frontiers on modern drug delivery. In recent years, nano drug co-delivery system (NDCDS), which loads at least two anticancer drugs with different physicochemical and pharmacological properties into a combination delivery system, has achieved rapid development. NDCDS synergistically inhibited the growth of the tumor compared with the free drugs. In this review, we highlighted the current state of co-delivery nanoparticles and the most commonly used nanomaterial, discussed challenges and strategies, and prospect future development.

Keywords

Combination chemotherapy drug delivery materials multidrug resistance (MDR) nano drug co-delivery system (NDCDS) targeting nanoparticles

References

Adv Drug Deliv Rev. 2015 Jan;81:184-97 [PMID: 25281917]
J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8 [PMID: 16234567]
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 [PMID: 26742998]
Mol Pharm. 2015 Nov 2;12(11):4085-98 [PMID: 26422373]
Int J Pharm. 2015 Nov 30;495(2):932-9 [PMID: 26456262]
Adv Drug Deliv Rev. 2016 Mar 1;98:41-63 [PMID: 26529199]
CA Cancer J Clin. 2016 Jul;66(4):271-89 [PMID: 27253694]
Mater Sci Eng C Mater Biol Appl. 2016 Dec 1;69:1092-102 [PMID: 27612807]
Macromol Biosci. 2013 May;13(5):584-94 [PMID: 23420692]
J Control Release. 2012 Oct 28;163(2):130-5 [PMID: 22981564]
J Control Release. 2017 Oct 10;263:223-230 [PMID: 28034787]
J Am Chem Soc. 2014 Apr 9;136(14):5181-4 [PMID: 24669930]
Nat Rev Cancer. 2005 Sep;5(9):726-34 [PMID: 16148885]
Drug Resist Updat. 2006 Jun;9(3):157-73 [PMID: 16822706]
Biomaterials. 2014 Jul;35(23):6118-29 [PMID: 24794923]
Acta Biomater. 2017 Aug;58:349-364 [PMID: 28455219]
J Control Release. 2013 Aug 10;169(3):185-92 [PMID: 23403395]
Mater Sci Eng C Mater Biol Appl. 2016 Jul 1;64:208-218 [PMID: 27127046]
J Agric Food Chem. 2011 Sep 14;59(17):9280-9 [PMID: 21797282]
Biomaterials. 2011 Nov;32(32):8281-90 [PMID: 21807411]
Int J Nanomedicine. 2015 Oct 22;10:6615-32 [PMID: 26543365]
Biomaterials. 2010 Dec;31(34):9086-91 [PMID: 20828812]
J Control Release. 2015 Oct 28;216:9-17 [PMID: 26272764]
Int J Nanomedicine. 2014 Sep 15;9:4357-73 [PMID: 25258527]
Biomacromolecules. 2014 Mar 10;15(3):756-62 [PMID: 24460101]
Chem Commun (Camb). 2015 Nov 7;51(86):15649-52 [PMID: 26360641]
J Control Release. 2015 Dec 28;220(Pt A):545-555 [PMID: 26590021]
J Control Release. 2012 Jul 20;161(2):505-22 [PMID: 22353619]
Gan. 1975 Dec;66(6):719-20 [PMID: 1225724]
Int J Pharm. 2015 Jul 5;488(1-2):44-58 [PMID: 25899286]
FEBS Lett. 1973 Nov 1;36(3):292-6 [PMID: 4763309]
Drug Deliv. 2012 Nov;19(8):363-70 [PMID: 23030458]
Mol Pharm. 2016 Feb 1;13(2):663-76 [PMID: 26695934]
Biomaterials. 2014 Mar;35(9):3005-14 [PMID: 24388813]
Biomaterials. 2017 Feb;117:54-65 [PMID: 27936417]
Nat Rev Cancer. 2002 Jan;2(1):48-58 [PMID: 11902585]
Macromol Biosci. 2015 Sep;15(9):1252-61 [PMID: 25981672]
Cell Res. 2007 Feb;17(2):89-99 [PMID: 17242688]
Biomaterials. 2014 Nov;35(33):9144-54 [PMID: 25109439]
Mol Pharm. 2011 Jun 6;8(3):852-66 [PMID: 21480667]
Ther Deliv. 2010 Aug;1(2):323-34 [PMID: 22816135]
Macromol Biosci. 2014 Aug;14(8):1106-15 [PMID: 24771682]
Pharm Res. 2014 Aug;31(8):1938-45 [PMID: 24522815]
Nano Today. 2012 Aug 1;7(4):367-379 [PMID: 26257819]
Biomaterials. 2016 Oct;103:44-55 [PMID: 27376558]
Colloids Surf B Biointerfaces. 2017 Mar 1;151:119-127 [PMID: 27988472]
Int J Pharm. 2013 Sep 15;454(1):486-95 [PMID: 23792465]
ACS Nano. 2014 May 27;8(5):4996-5009 [PMID: 24720540]
Mol Pharm. 2014 Nov 3;11(11):4118-29 [PMID: 25222114]
Adv Drug Deliv Rev. 2016 Mar 1;98:19-34 [PMID: 26546751]
Colloids Surf B Biointerfaces. 2016 Sep 1;145:716-727 [PMID: 27289313]
Biomaterials. 2013 Jul;34(21):5149-62 [PMID: 23578555]
Biomaterials. 2013 Apr;34(12):3150-8 [PMID: 23369218]
Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59 [PMID: 17428165]
Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3553s-5s [PMID: 16740784]
Biomaterials. 2013 Apr;34(11):2719-30 [PMID: 23337327]
Sci Rep. 2016 May 06;6:25468 [PMID: 27151505]
Eur J Pharm Sci. 2017 Jan 1;96:351-361 [PMID: 27721039]
Crit Rev Biotechnol. 1997;17(2):105-22 [PMID: 9192473]
J Pharm Pharm Sci. 2012;15(4):568-82 [PMID: 23106959]
Adv Drug Deliv Rev. 2016 Mar 1;98:35-40 [PMID: 26724249]
ACS Nano. 2013 Jul 23;7(7):5858-69 [PMID: 23734880]
Biomaterials. 2012 Mar;33(9):2780-90 [PMID: 22243797]
Autophagy. 2007 Jan-Feb;3(1):28-31 [PMID: 16969128]
Colloids Surf B Biointerfaces. 2016 Sep 1;145:526-538 [PMID: 27281238]
Biomaterials. 2015 Dec;72:74-89 [PMID: 26344365]
J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302 [PMID: 10944550]
Pharmacol Res. 2016 Mar;105:164-75 [PMID: 26826398]
Biomaterials. 2015 Jan;37:456-468 [PMID: 25453973]
Biomaterials. 2014 Feb;35(6):1932-43 [PMID: 24315578]
Colloids Surf B Biointerfaces. 2014 Nov 1;123:345-63 [PMID: 25280609]
Int J Pharm. 2014 Apr 10;464(1-2):178-84 [PMID: 24440402]
Nat Mater. 2006 Oct;5(10):791-6 [PMID: 16998471]
Cancer Res. 2010 Jan 15;70(2):440-6 [PMID: 20068163]
J Control Release. 2017 Jul 28;258:108-120 [PMID: 28522191]
J Drug Target. 2017 Nov - Dec;25(9-10):796-808 [PMID: 28726521]
Drug Deliv. 2016 May;23(4):1130-43 [PMID: 25491241]
Int J Pharm. 2016 Feb 10;498(1-2):70-81 [PMID: 26657275]
Cancer Lett. 2017 Aug 10;401:63-71 [PMID: 28476483]
J Pharm Pharm Sci. 2007;10(3):350-7 [PMID: 17727798]
Nat Rev Cancer. 2012 Mar 22;12(4):278-87 [PMID: 22437872]
Ann Intern Med. 1970 Dec;73(6):881-95 [PMID: 5525541]
ACS Appl Mater Interfaces. 2011 Mar;3(3):842-56 [PMID: 21370886]
Acta Biomater. 2015 Oct;25:162-71 [PMID: 26190797]
Nanoscale. 2012 Nov 21;4(22):7185-93 [PMID: 23070403]
Adv Drug Deliv Rev. 2016 Mar 1;98:3-18 [PMID: 26546465]
Nanomedicine. 2016 Jul;12(5):1279-90 [PMID: 26772427]
Adv Drug Deliv Rev. 2016 Mar 1;98:64-76 [PMID: 26546464]
Cancer Treat Rev. 2003 Dec;29(6):515-23 [PMID: 14585261]
Mater Sci Eng C Mater Biol Appl. 2016 May;62:564-73 [PMID: 26952460]
Int J Pharm. 2011 Sep 15;416(1):296-9 [PMID: 21703341]
Nanomedicine. 2014 Jan;10(1):99-107 [PMID: 23891983]
Biochem J. 1971 Oct;124(5):58P [PMID: 5130994]
J Control Release. 2012 Jun 10;160(2):281-9 [PMID: 22019556]
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 [PMID: 24399786]
Macromol Biosci. 2015 Nov;15(11):1497-506 [PMID: 26184375]
Eur J Pharm Biopharm. 2014 Nov;88(3):1086-93 [PMID: 25305583]
Eur J Pharm Biopharm. 2014 Oct;88(2):539-50 [PMID: 25016976]
Biomaterials. 2009 Feb;30(5):919-27 [PMID: 19042015]
J Control Release. 2011 Nov 30;152 Suppl 1:e64-5 [PMID: 22195930]
J Nanobiotechnology. 2015 Sep 22;13:57 [PMID: 26395758]
Biomed Pharmacother. 2017 Apr;88:374-383 [PMID: 28122302]
Free Radic Biol Med. 2003 Apr 15;34(8):955-68 [PMID: 12684081]
Theranostics. 2014 Aug 15;4(11):1085-95 [PMID: 25285162]
J Clin Oncol. 2005 Jan 1;23(1):190-6 [PMID: 15625373]
Int J Nanomedicine. 2017 Mar 16;12:2081-2108 [PMID: 28356731]
Adv Drug Deliv Rev. 2016 Mar 1;98:77-85 [PMID: 26656604]
J Control Release. 2012 Nov 10;163(3):304-14 [PMID: 22698937]

MeSH Term

Animals
Antineoplastic Agents
Drug Delivery Systems
Humans
Nanoparticles
Nanotechnology
Neoplasms

Chemicals

Antineoplastic Agents
Journal Article Review

Word Cloud

Similar Articles

Cited By